All News

obese.waist_.jpg

Weekly Semaglutide for Weight Loss in Adults

d Jack Cush, MD

NEJM has reported the results of a trial showing semaglutide once weekly plus lifestyle intervention was associated with sustained, weight loss in overweight or obese adults; such that nearly one-third lost over 20% of their body weight.

Read Article
RWCS 2021

RWCS Highlights - Day 1

d Rachel Tate, DO

The 2021 Rheumatology Winter Clinical Symposium launched yesterday as a hybrid meeting. As always, this conference lends itself to data for the practical clinician. Here are my pearls about new developments in RA, checkpoint inhibitors and IV IgG taken from several sessions presented on Day 1.

Read Article
A serious shortage of pediatric rheumatologists in the USA, where we need at least 1 ped rheum per 400,000 population. @RWCSmtg https://t.co/o8XCkjUOaN
Dr. John Cush RheumNow ( View Tweet)
CARRA was established in 2000 to further pediatric Rheumatology through research and registries @RWCSmtg https://t.co/drXGz23QyN
Dr. John Cush RheumNow ( View Tweet)
Milestone achievements of the pediatric Rheumatology collaborative study group @RWCSmtg https://t.co/OGXd2YWj5A
Dr. John Cush RheumNow ( View Tweet)
Dr. Anne Stevens lecturing at @RWCSmtg on the history of pediatric Rheumatology. Sir Eric Bywaters was the Father of meeting day pediatric Rheumatology @RWCSmtg https://t.co/iZtPfgoyxa
Dr. John Cush RheumNow ( View Tweet)
Dr George F Still, among the first to write about children with arthritis, pediatric Rheumatology, in 1898, with his description of 22 kids with arthritis. @RWCSmtg https://t.co/Y6DOzooFjZ
Dr. John Cush RheumNow ( View Tweet)
EXCEED study in #PsA shows lower responses in women (vs men) treated with either secukinumab or adalimumab. Question is, why? @RWCSmtg @JointMD https://t.co/LFBQi1jtiu
Dr. John Cush RheumNow ( View Tweet)
In #PsA does it matter if you're on background MTX when treated with ixekizumab or adalimumab? MTX does augment ADA responses but it's not needed with IXE @RWCSmtg @JointMD https://t.co/9GpKjLS4ao
Dr. John Cush RheumNow ( View Tweet)
No increased risk of cancer with TNFi use in PsA patients @RWCSmtg @JointMD https://t.co/7VSI1Fd1hw
Dr. John Cush RheumNow ( View Tweet)
Partial control of #PsA on MTX- Control study shows that adding adalimumab is superior to just escalating MTX @RWCSmtg @JointMD https://t.co/nDWzf4HYwp
Dr. John Cush RheumNow ( View Tweet)
Drs. Kavanaugh, Ruderman, Ogdie at @RWCSmtg on the multiple domains of psoriatic arthritis #PsA @JointMD https://t.co/3uS6JxdfIR
Dr. John Cush RheumNow ( View Tweet)
RWCS Highlights - Day 1 (@uptotate) The 2021 Rheumatology Winter Clinical Symposium (RWCS) launched yesterday as a hybrid meeting. Led by exceptional teachers and researchers in rheumatology, this live and streaming conference had many highlights. https://t.co/eKSsrXmLvu https://t.co/Gy9YEaK6Z1

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients The ACR has published a draft guidance on the use of COVID-19 vaccination in RMD patients, based on the efforts of the North American Task Force. https://t.co/uSPfvJB8EC https://t.co/9bwBdtHw5e

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - Fever by the Numbers Diagnosis of Periodic Fever by Fever Duration https://t.co/q3ZmJLrgOO

Links:

Dr. John Cush RheumNow ( View Tweet)

Defects in NLRC4 inflammasome can drive IL 18 production in systemic JIA. @RWCSmtg https://t.co/ffzODTXd52

Dr. John Cush RheumNow ( View Tweet)
309 RA pts from the Preconception Counseling in Active RA (PreCARA) cohort were treated according to a modified T2T approach, 188 children were born. 47% of pts were on a TNFi during Preg; 75% were in LDAremission before PREG but 90% by 3rd trimester https://t.co/eLffxrH0UV

Links:

Dr. John Cush RheumNow ( View Tweet)

Preprint from UK trial shows tocilizumab efficacy in COVID-19. 2022 TCZ vs 2094 usual care pts (also on dexamethasone), in hospitalized pts on ventilators. 28 day mortality was 29% on TCZ Vs 33% with usual care - TCZ had 23% incr probability of discharge https://t.co/Curd6W20qK https://t.co/0TbhJYh5vM

Links:

Dr. John Cush RheumNow ( View Tweet)
Upadacitinib works very well in ankylosing spondylitis. Will JAKs soon be approved in #AS @RWCSmtg @JointMD https://t.co/09KFo3mYJs
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib shown to work very well in ankylosing spondylitis. @RWCSmtg @JointMD https://t.co/r1yIL96HyQ
Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×